World Biosimilars Congress

11 - 13 September 2012
Jumeirah Carlton Tower, London, UK

Strategies for navigating the regulatory, manufacturing, sales and marketing route to biosimilar and biobetter market entry

Biosimilars: maximise the potential within your research portfolio

The 2012 World Biosimilars Congress is Europe’s first commercially orientated conference that tackles all the key strategic and best practice issues facing the Biosimilar industry.

World Biosimilars Congress Europe is where decision-makers from all the big pharmaceutical companies, the key mid cap biotechs, major generic and regional generic companies, pioneering academic institutions, government officials, investment professionals and the wider contract service community meet to learn and plan for the future.

Download the brochure ›
Register for the World Biosimilars Congress 2012 ›

The 2012 topics and themes

Strategic considerations for biosimilar market entry
Regulatory environment and EU biosimilar guidelines
Product development, clinical data, immunogenicity and pharmacovigilance
Research-based industry biosimilar strategies
Role of contract service providers and strategic partnerships
Product selection, regulatory expertise, CMC, clinical development and successful commercialisation
Intellectual property and biosimilar-specific patent environment
Biosimilar commercialisation, uptake and pricing structures